SSY GROUP (02005) has obtained the drug production registration approvals for four products, including Potassium Chloride Injection (II) (100ml: 1.5g) and Sodium Hyaluronate Eye Drops 0.3% (0.4ml: 1.2mg).

SSY GROUP (02005) announced that the group has obtained the drug production registration approval from the National Medical Products Administration of China for the following four products, all of which are deemed to have passed the consistency evaluation. 1. Potassium Chloride Injection () (100ml: 1.5g): This product is the second approved by domestic enterprises and falls under Class 3 chemical drugs, mainly used for treating hypokalemia when oral potassium supplementation is not possible. This product further enriches the groups therapeutic infusion product matrix, strengthening the groups product layout and specialty clinical supply capabilities in intensive care units (ICU). 2. Sodium Hyaluronate Eye Drops 0.3% (0.4ml: 1.2mg): This product belongs to Class 4 chemical drugs and is mainly used to treat epithelial damage of the cornea and conjunctiva associated with the following conditions: Sjgren's syndrome, Stevens-Johnson syndrome, dry eye syndrome, and other endogenous disorders; as well as exogenous disorders such as postoperative, drug-induced, trauma, and wearing contact lenses. 3. Sodium Hyaluronate Eye Drops 0.1% (0.4ml: 0.4mg): This product also belongs to Class 4 chemical drugs and is primarily used for dry eye syndrome to relieve dry eye symptoms. Both sodium hyaluronate eye drops are packaged in single-dose preservative-free formats. Together with the previously approved polyvinyl alcohol eye drops, they create a product combination that covers different severities of dry eye syndrome, providing patients with tiered treatment options. The group strategically lays out a preservative-free single-dose formulation in the ophthalmic medication sector, having established a product matrix that includes anti-infectives, anti-allergy agents, intraocular pressure-reducing agents, artificial tears, and ocular anti-inflammatory medications, forming a dual-channel layout for hospital prescription drugs and retail OTC. 4. Metoclopramide Tablets (5mg): This product belongs to Class 3 chemical drugs and is mainly used for symptomatic treatment of nausea and vomiting caused by various etiologies, short-term treatment of symptomatic gastroesophageal reflux that is unresponsive to conventional therapy, and relief of symptoms of acute and recurrent diabetic gastroparesis. As noted in the companys announcement dated February 27, 2026, the groups metoclopramide raw material has been approved by the National Medical Products Administration for registration as an active pharmaceutical ingredient used in marketed formulations.